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SUMMARY  
Respiratory syncytial virus (RSV) infection has an estimated global incidence of 33 million 
cases in children younger than 5 years, with 10% requiring hospital admission and up to 
199,000 dying of the disease.  There is growing evidence that severe infantile RSV 
bronchiolitis, a condition characterised by an inflammatory reaction to the virus, is 
associated with later childhood wheeze in some vulnerable children; however, a direct 
causal relationship with asthma has not yet been established. It is also increasingly 
recognised as a cause of morbidity and mortality in those with underlying airway disease, 
immunocompromise and frail elderly persons. Novel molecular based diagnostic tools are 
becoming established but treatment largely remains supportive, with palivizumab being the 
only licensed agent currently available for passive prophylaxis of selected pre-term infants. 
Whilst effective treatments remain elusive, there is optimism about the testing of novel 
antiviral drugs and the development of vaccines that may induce long-lasting immunity 
without the risk of disease augmentation. 
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INTRODUCTION 
Since its discovery in 1956, respiratory syncytial 
virus (RSV) has become recognized as a leading 
global cause of morbidity and mortality, especially 
amongst infants in the first six months life. RSV is 
the commonest cause of childhood acute 
respiratory infection (ARI) and the major single 
cause of hospitalization during infancy. In recent 
decades, it has been realized that it also afflicts 
various at-risk adults, including frail elderly and 
immunocompromised persons. In resource-poor 
settings, it is an important cause of death due to 
due to lower respiratory tract infection, second 
only to pneumococcal pneumonia and H. 
influenzae type B. Resource-limited countries have 
more than twice the incidence severe disease seen 
in developed countries and, remarkably, 99% of 
the global deaths caused by RSV infection (1).  
Given this appalling disease toll and the fact that 
current treatment is simply supportive, it is clear 
that prevention, early diagnosis and the discovery 
of specific therapies has enormous potential to 
improve global health amongst the most 
vulnerable in society. RSV remains one of the last 
major viruses for which we currently (in early 
2016) have no safe and effective vaccine.    
Not only does RSV cause acute disease, but those 
with severe infections can apparently be left with 
long term sequelae. These include persistent 
wheeze and in some cases established 
inflammatory airway disease (2,3), highlighting the 
importance of understanding which immune 
responses correlate with protection and what 
makes some individuals at risk of severe or 
delayed disease. Molecular techniques such as real 
time PCR (qPCR) have now become more 
affordable and offer rapid and accurate 
diagnostics, with the ability to identify the disease 
earlier in at-risk patients, at levels of viral burden 
too low for conventional detection and affording 
the potential for community-based epidemiology 
(4,5). Intensive research in recent decades has 
accelerated progress on many fronts, with several 
promising new vaccines in advanced stages of 
development (6,7). In countries with limited access 
to healthcare, an effective and affordable vaccine 
would be transformative.   
 
 
EPIDEMIOLOGY 
RSV causes significant morbidity and mortality 
across the globe and is the leading cause of 
pneumonia and bronchiolitis in infants. In addition 
to a currently poorly quantified burden in the 
elderly, it is estimated to cause 30 million acute 
respiratory infections and more than 60,000 
childhood deaths worldwide each year (1,8). The 
main burden of disease is in the under 5 age group 
but RSV has considerable impact on various at risk 
adult populations (9,10).  In the USA, RSV is 
estimated to cause 17,358 deaths per year, 22 % 
of which are in persons less than 65 years of age 
(11). 
Seasonality        
Seasonality of RSV infection varies across the 
globe. Temperate zones tend to experience RSV 
epidemics during late autumn, winter and/or 
spring (12) whereas tropical and arctic climates see 
less well defined annual variation with year-round 
disease described in some settings (13). In 
northern tropical areas the seasonality is 
associated with a decrease in temperature and 
increase in rainfall, whereas in more tropical 
climates yearly outbreaks can occur during the 
warm and rainy seasons (see figure 1) (14,15).  
In Europe, RSV is predominantly a disease of 
winter with peaks of illness in December and 
January in the United Kingdom, Belgium, Germany 
and the Netherlands with a later peak of March in 
Mediterranean countries such as Greece (16,17); 
biennial cycles of RSV activity have been described 
in northern Europe (15). The association of an 
increase in RSV cases with declining temperatures 
has been attributed to increased indoor crowding 
leading to enhanced viral transmission, to lower 
temperatures increasing viral stability and to 
chilling increasing host susceptibility or activation 
of dormant virus (18).
 
 Figure 1. Annual cycle of global peak RSV incidence and associated climactic factors. Temperate countries 
typically have peak incidence of RSV during their winter months, which are associated with lower 
temperatures, higher rainfall and higher humidity. There is greater variability in tropical regions, which are 
prone to biennial and perennial RSV. Limited information is available for some regions, e.g. Africa. Data from 
[12–15]. 
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Infants and Children 
Pneumonia is the leading cause of mortality of 
children worldwide with RSV being the commonest 
single cause of acute respiratory infection (ARI) in 
young children (8,19). By 18 months of age, 87% of 
children have antibodies to RSV and by the age of 
3 years, virtually all children have been infected 
(20). 
A large meta-analysis estimated there to be 33.8 
million cases of RSV associated ARI worldwide in 
2005 in children less than 5 years of age but this is 
likely to be an underestimate; previous studies 
using active methods for data collection, such as 
home visits, have shown much higher incidence 
rates (1). In the USA, RSV has been estimated to 
account for 20% of acute respiratory infection 
hospitalisations in children under 5 (17 per 1000 
children under 6 months and 3 per 1000 under 5)  
 
but 99% of RSV deaths occur in low-income 
countries with a lack of access to basic, supportive 
care being a key factor (1,8). Children are at 
highest risk of death in the first 6 months of life 
(11). 
The majority of children suffering from RSV ARI 
have no underlying comorbidities. Low birth 
weight and prematurity are major risk factors for 
hospitalisation, as is congenital or acquired 
immunodeficiency and various cardiopulmonary, 
chronic lung disease and neurodevelopmental 
disorders (21,22). Environmental factors 
contributing to increased susceptibility are side-
stream tobacco smoke exposure, lack of 
breastfeeding and low socioeconomic status (23). 
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Adults and Elder Persons 
There remains no globally accepted definition or 
reliable classification of acute respiratory infection, 
making it difficult to compare studies and to make 
accurate estimates of disease burden. Adding to 
these problems, variations in sampling 
methodology and diagnostic testing across studies 
provides further hurdles. With major differences in 
healthcare provision and access to resources in 
different geographical and socioeconomic settings, 
it is difficult to estimate the true impact of RSV 
disease in diverse settings.  Despite these caveats, 
we can state with reasonable certainty that it is 
rare for healthy immunocompetent adults to 
require hospitalisation due to RSV infection.  
However, infection with RSV is so prevalent that it 
is estimated to cause a disease burden at least 
comparable to influenza in elderly persons (24). 
Given the aging population structure in Western 
countries, adult RSV-associated mortality is 
becoming an ever greater problem that poses a 
huge health and economic burden (9,11). A recent 
north-American study examined the impact of RSV 
during four consecutive winters amongst healthy 
elderly patients (n=608), high-risk adults (those 
with chronic heart or lung disease, n= 540) and 
patients hospitalised with acute respiratory illness 
(n=1388). The average age across all groups was 
more than 70 years; RSV infection developed 
annually in 3-7% of healthy elderly patients, 4-10% 
of high-risk adults and was present in 8-13% of 
patients hospitalised with acute respiratory 
infection. During the study period, RSV infection 
accounted for 11 % of hospitalizations for 
pneumonia, 11 % for chronic obstructive 
pulmonary disease (COPD), 5 % for congestive 
heart failure, and 7 % for asthma (10). In the UK, it 
is estimated that amongst the adult population, 
those over the age of 65 account for 36 % of GP 
episodes, 79% of hospitalisations and 93% of 
deaths due to RSV each season and RSV was 
responsible for more morbidity than influenza 
(24). Globally, RSV accounts for 7.4% of elderly 
(>65 years) individuals presenting with influenza-
like-illness (25). 
The Immunocompromised 
In both children and adults, various 
immunodeficiency states predispose to RSV 
infection and disease. In addition to HIV-infected 
children being liable to develop RSV-ARI, they are 
3.5 times more likely to be hospitalized than non 
HIV infected children (21), are more likely to 
present with pneumonia, have greater evidence of 
bacterial co-infection and higher mortality rates 
than HIV-uninfected children (26). RSV is a 
common cause of ARI in haematopoietic stem cell 
transplant (HSCT) patients, with rates of infection 
being as high as 2-17% in some settings. As well as 
increased susceptibility to infection, these patients 
are also liable to progress to more severe disease. 
RSV pneumonia in this patient group has a 
mortality of up to 83% (27). Factors linked to 
severity and poor outcome include male sex, the 
type of graft (allogeneic), myeloablative regimen, 
cytomegalovirus seropositivity, increasing age, 
unrelated donor transplant, graft-versus-host 
disease (GVHD) and becoming infected within the 
first 3 months of transplant (28). 
 
VIROLOGY 
RSV is an enveloped virus that belongs to the 
genus Pneumovirus, family Paramyxoviridae. It is a 
negative sense, single stranded RNA virus 
consisting of 11 proteins encoded by a 15.2-kb RSV 
genome.  It has a non-segmented genome so, 
unlike influenza, it does not have the capacity for 
re-assortment of genome segments and thus to 
undergo antigenic shifts that have the potential to 
cause large pandemics. 
RSV was originally characterized in 1956 from a 
colony of chimpanzees with coryza and termed 
chimpanzee coryza agent (29). It was later isolated 
from a number of infants and recognized as being 
a human virus that caused mild illness in a 
susceptible group of chimpanzees (30). It was re-
termed respiratory syncytial virus, as it causes cells 
to fuse with neighboring cells, creating large 
multinucleated syncytia. 
RSV has been classified into two distinct subgroups 
(A and B), based on antigenic variability (31). These 
two groups have been described based on the 
reactions of two major surface proteins to 
monoclonal antibodies; the G protein facilitates 
viral attachment to host ciliated cells of the airway 
(32)while F mediates virion and host cell fusion 
(33).  
Additional antigenic variability occurs within the A 
and B subgroups with the most extensive antigenic 
and genetic diversity being found in the 
attachment glycoprotein G, therefore playing a 
significant role in RSV pathogenicity and immune 
evasion. RSV subtype A viruses may be marginally 
more virulent and may replicate to higher titers 
than the group B viruses in vivo and in vitro (34). 
New RSV genotypes appear periodically and tend 
ERS Monograph: Respiratory Syncytial virus  
5 
 
to predominate and replace the circulating strain 
of RSV. However the original circulating strain does 
not become extinct, with new and old genotypes 
occurring alongside each other for relatively long 
periods (35).  
Viral Structure and Proteins 
RSV particles are pleomorphic with both spherical 
and filamentous particles of different sizes (36). 
The virions display three surface proteins: F, G and 
SH (small hydrophobic) (figure 2) (37). Proteins G 
and F are integral for virion attachment and fusion; 
binding to disaccharide subunits called GAGs and 
RhoA respectively (38,39). Following fusion the 
virion releases the nucleocapsid into the cytosol, 
enabling the RNA to enter the host cell. The M2 
mRNA has two overlapping ORFs encoding M2-1 
and M2-2. The M2-2 gene governs the transition 
from transcription to production of genomic RNA 
(40). The large (L) protein is a viral RNA-dependent 
RNA polymerase that contains multiple enzyme 
functions required for RSV replication, it enters the 
genome and mRNA is transcribed. Replication 
generates a complete positive-sense RNA 
complement of the genome – the antigenome that 
acts as a template for replication. Throughout 
replication the N protein encapsulates the RNA, 
which prevents degradation. M protein co-
ordinates the assembly of the envelope proteins 
with the nucleocapsid proteins (N, P, and M2-1) 
and facilitates budding of new immature virions 
using the host cell membrane. Filamentous virions 
show a helical assembly of M (matrix) proteins 
that play a critical role in formation of infectious 
filamentous particles (41). 
 
 
 
PATHOGENESIS 
RSV is a highly contagious virus and can cause 
outbreaks both in the community and hospital 
setting (42,43). Infection begins via inoculation of 
the nose or eyes via large particle or direct 
contact, with an incubation period of 2-8 days. RSV 
can survive for prolonged periods on skin, cloth, 
and other objects thereby facilitating its spread 
(44). How it survives so well is puzzling, since lab-
grown virus is notoriously unstable at room 
temperature (45).  
RSV infects the ciliated epithelial cells of the upper 
and lower respiratory tract.  In the lower airways 
the virus specifically targets the ciliated cell of the 
bronchioles, but can also be found in type 1 
pneumocytes and intraepithelial dendritic cells. 
More recently it has been demonstrated that RSV 
can infect basal cells (the progenitors for the 
conducting airway epithelium) where it has the 
potential to influence the morphogenesis of the 
airway epithelium(46). 
Infection causes widespread inflammation with 
peribronchial monocyte and T-cell infiltration, 
epithelial necrosis, sub mucosal edema and 
mucus-overproduction (47). Infection and tissue 
damage tends to be patchy rather than diffuse. 
Airway obstruction occurs in the small airways 
secondary to sloughing of epithelial cells, mucus 
plugs and accumulated luminal and intraluminal 
immune cells. Additionally, syncytia are 
occasionally observed, more commonly in 
immunocompromised patients (48). The degree to 
which this depends on viral or host variation is 
currently poorly understood. Possibly, the 
development of severe disease results from an 
Figure 2. Diagrammatic cross-section through an 
infectious RSV filament. ss: single-stranded. 
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unfortunate collision of a particular viral strain 
with a host that responds adversely to that specific 
strain.  
Environmental Factors 
Environmental factors include exposure to tobacco 
smoke, air pollution and indoor crowding (day care 
attendance, nursing home or hospital stay); the 
presence of an older sibling is an independent risk 
factor for the development of RSV disease in 
infancy (16). There have been many studies that 
have documented the link between tobacco smoke 
and RSV infection. A 2012 systematic review of 30 
studies reported that tobacco smoke exposure 
places infants and young children at increased risk 
of hospitalization for RSV-attributable lower 
respiratory tract infection, in addition to increasing 
the severity of illness (49). The association 
between air pollution and severe RSV disease is 
also well documented. It has been shown in vivo 
that diesel engine emissions cause a more 
pronounced peribronchial/bronchiolar 
inflammation with increased mucous cell 
metaplasia in the context of RSV infection (50). 
 Viral Factors 
There is a well-documented correlation between 
the level of virus replication and severity of 
infection (51,52). Unlike other viruses, immunity to 
RSV infection is incomplete and short-lived, and 
reinfection is common throughout life. This is not 
largely attributable to viral evolution in response 
to host immunity; instead, RSV seems to be able to 
modulate and evade the immune system. It does 
this in several ways.  The G protein is key to this; 
being present in membrane-bound and secreted 
forms. Secretory protein G acts as a decoy, aiding 
with virus evasion of antibody-mediated 
neutralization(53). It also exhibits a CX3C 
fractalkine like motif which binds to chemokine 
receptor CX3CR1 inducing leucocyte chemotaxis 
(54). Additionally the cysteine rich portion of G 
protein is directly able to inhibit signaling from toll 
like receptors (2, 4, and 9) all of which reduce the 
host immune response.  
Furthermore two nonstructural (NS) proteins NS1 
and NS2 which are highly expressed during early 
RSV infection, down-regulate interferon 
production and apoptosis leading to enhanced 
viral replication (55). The small hydrophobic (SH) 
transmembrane protein increases membrane 
permeability and to a lesser extent has also been 
linked to decreased apoptosis(56). Within the 
virion, RNA is tightly bound by N protein and this is 
thought to prevent degradation and also aid with 
concealment from pattern recognition receptors, 
promoting infectivity in host cells. 
Host factors 
Multiple factors can increase susceptibility to RSV 
infection and are associated with a more severe 
disease course. These include premature birth, 
comorbidities (cardiac and respiratory), 
immunodeficiency and age. There is increasing 
evidence that there may be some genetic 
associations of RSV susceptibility and severity. For 
example, it has been shown that identical twins 
are often concordant for severe RSV disease. The 
host genetic contribution for this propensity is 
estimated to account for approximately 20% of the 
variance (57). 
The genetic polymorphisms that affect RSV 
pathogenesis often lie in genes involved in innate 
defences, surfactant proteins, host cell receptors, 
neutrophil responses, Th1/Th2 responses and 
other components of adaptive immunity (58). 
Ongoing large genome-wide approaches are likely 
to further improve our knowledge in this area. 
 
IMMUNE RESPONSE 
As described previously, virtually all children have 
been infected by the age of 2; most 
immunocompetent children clear the infection 
within 3 weeks (59). Some infants are predisposed 
to more severe infection and those infected in the 
first 6 months are subsequently prone to wheeze 
until at least 6 years of age (3), and possibly 
through to adulthood (2). 
Early Immune Responses 
The recognition of pathogen-associated molecular 
patterns (PAMPs) present on viruses by pattern 
recognition receptors (PRRS) such as Toll-like 
receptors (TLRs) and RNA-sensing RIG-I– like 
receptors (RLRs) leads to the release of 
antimicrobial mediators by the host mucosal 
immune system and serves to form an effective 
first line of resistance against infection. Type 1 
responses are characterized by release of type I 
IFNs (IFN-α and IFN-β) and Type III IFNs (IFN-λ1, 
IFN-λ2, IFN-λ3(60)). These are potent antiviral 
mediators induced early in infection from 
epithelial cells and resident immune cells with 
alveolar macrophages recently being discovered in 
a murine model to be major contributors to IFN 
production leading to the subsequent recruitment 
of inflammatory monocytes to the lungs (61). 
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Dendritic cells are also key to bridging innate and 
adaptive responses by transporting viral antigens 
to cervical and pulmonary lymph nodes and 
presenting them to CD4
+
 T-cells, which in turn 
activates CD8
+
 T-cells and B-lymphocytes. They 
return to the site of infection to further promote 
local induction of pro-inflammatory mediators and 
cellular efflux (62).    
There is debate about whether defective or 
exuberant immune responses are responsible for 
the infection spreading from a limited mucosal 
infection (in most people) to more extensive lung 
immunopathology or even extrapulmonary 
manifestations (in susceptible individuals) (63–65). 
An insufficient type 1 response as well as 
exaggerated type 2 responses (characterised by IL-
4, IL-5 and IL-13) have been implicated in causing 
susceptibility to RSV bronchiolitis (66,67) and an 
inability to produce sufficient IFN-γ early in life 
may increase risk of developing severe disease 
(68). Gene polymorphisms of TLR4, IL-4 receptor α 
and IL-8 have also been associated with severe RSV 
bronchiolitis, highlighting the important role of 
innate immunity, although their biological role in 
active disease is yet to be fully understood (69–
71).  
The naieve immune system of infants is 
characeterized by hyporesponsiveness to 
infections and viral mimetic stimuli in vitro when 
compared to adults (64,72) with premature infants 
of less than 35 weeks gestational age being at the 
highest risk due to compromised pulmonary 
development and deficient serum 
immunoglobulins (73). In term infants, maternal 
specific RSV-neutralizing antibodies are present 
from the third trimester and are stable until birth, 
with higher cord blood levels being protective 
against RSV infection although only protective for 
the first 6 months of life (74). 
Established Infection, Reinfection and Resolution 
Once infection is established, cellular immunity 
and immunoregulation plays a critical role in 
promoting viral clearance and limiting pathology, 
which is clearly demonstrated in paediatric 
patients with primary or acquired 
immunodeficiency who have a much longer 
duration of infection and can shed virus for several 
months (75,76). Classically, helper T cells that 
make interferon gamma (Th1 Cells) are important 
in antiviral defense, but it is possible that other 
helper T cell subsets contribute towards 
eliminating the virus (77). In particular, IL-10 
producing cells inhibit disease and inflammation in 
mice infected with RSV, especially during recovery 
(78). Cytotoxic CD8
+
 lymphocytes (CTLs) may cause 
neutrophil efflux (79,80) whilst more abundant 
airway resident memory T cells (Trm) at baseline 
correlate with reduced viral load and symptoms 
during experimental human adult infection (81). 
Interestingly, virus and T cell inflammation may 
remain present in asymptomatic convalescent 
volunteers in this model (81).  Certain macrophage 
subtypes (M2) and pDCs likely play an important 
role in modulating local immune responses and 
restricting T cell-mediated inflammation (82,83). 
The ability of RSV to re-infect may also be 
explained by defective RSV-specific IgA memory B 
cell responses (84,85). Some individuals suffer dual 
infection with RSV and other viruses, which can 
lead to greater severity of disease and is 
associated with decreased IFN-γ responses (86).  
It is thought that the increased susceptibility and 
severity of RSV in the elderly is secondary to 
immunosenescence, but how this occurs has not 
been fully defined. It has been shown that elderly 
and younger individuals have comparable RSV 
neutralization antibody titres, but there may be an 
impairment of T cell mediated immunity (87,88). 
Studies of RSV disease in mice indicate the 
importance of regulatory T cells (Treg) in 
maintaining an effective and non-pathogenic 
response to RSV infection, and have highlighted 
the dysregulation of immune responses that are 
characteristic of bronchiolitis (89). 
 
CLINICAL MANIFESTATIONS 
Acute Presentation in Children 
RSV infection in children can result in a range of 
disease phenotypes from mild upper respiratory 
tract symptoms to life-threatening lower airway 
involvement necessitating hospital admission and 
mechanical ventilation. Infants are at greater risk 
from RSV infection than older children with an 
increased likelihood of lower airway involvement 
in the form of both bronchiolitis and pneumonia 
(1). 
Clinical presentation of RSV often begins with 
typical upper respiratory tract signs and symptoms 
including coryza, cough and a febrile illness (90). 
On examination, a rhinitis and pharyngitis may be 
seen in association with conjunctival signs and 
erythema to the tympanic membrane (64). Less 
frequently bulging of the tympanic membrane may 
be seen if otitis media is also present. Nasal 
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congestion and generalised malaise can lead to 
poor feeding and subsequently dehydration (64). 
In approximately one third of infants with viral 
respiratory infections, progression to lower 
respiratory tract involvement is observed (64), 
most commonly in the form of bronchiolitis 
although pneumonia and laryngotracheitis (croup) 
can also develop (91). Bronchiolitis presents as 
worsening respiratory function with tachypnoea, 
wheeze and noisy breathing, as well as systemic 
viral features such as fever and lethargy (90,91). 
Some infants develop vomiting and poor feeding 
with dehydration (64). In young infants apnoea has 
also been described (92) and indeed may be the 
presenting symptom early in the disease. Signs of 
respiratory distress including nasal flaring, costal 
and intercostal recession and cyanosis, should be 
assessed for by clinicians in determining the need 
for admission to hospital in addition to other 
markers of disease severity including hydration 
status and level of alertness. Polyphonic expiratory 
wheeze and fine crepitations made be heard on 
auscultation of the chest (91). According to current 
guidelines, chest radiographs are not routinely 
performed in children with simple bronchiolitis but 
may show features of hyper-expansion including 
increased anterior-posterior diameter and 
diaphragmatic flattening as well as patchy bilateral 
infiltrates and atelectasis (figure 3) (90,93). 
Pneumonia with consolidation seen on chest x-ray 
can be due to the virus itself or a secondary 
bacterial infection. Extra-pulmonary 
manifestations of RSV are uncommon but have 
been described and include seizures, 
hyponatraemia, cardiac arrhythmia and failure and 
hepatitis (65). 
The differential diagnosis for children presenting 
with signs and symptoms of lower and upper 
respiratory infection includes other viral infections 
such as rhinovirus, metapneumovirus and 
influenza, primary bacterial pneumonia, congenital 
conditions such as cystic fibrosis, asthma and 
inhaled foreign bodies. 
 
 
   Figure 3. Chest radiograph of a 3-month-old infant with severe RSV bronchiolitis: demonstrating a collapsed 
right upper lobe, hyperinflated left lung and bilateral perihilar, peribronchial thickening. The patient is 
intubated and has a nasogastric tube in situ.  
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Longer Term Complications in Children 
In addition to the significant health burden of 
acute RSV infection, there is evidence of longer 
term consequences to respiratory function with 
the development of persistent airway disease. 
Although a causal relationship remains unclear, an 
association between RSV infection as an infant and 
subsequent wheezing, allergy and asthma, 
sometimes persisting into adulthood, has been 
demonstrated (2,90,94).  
Several longitudinal cohort studies have tracked 
the incidence of respiratory illness in children with 
RSV infection in infancy. The Tuscon Children’s 
Respiratory Study examined outcomes in children 
with clinician confirmed RSV lower respiratory 
tract infection (as defined by the presence of 
cough, wheeze, breathlessness, hoarseness or 
stridor, in the presence of an RSV positive 
diagnostic test) contracted up to the age of three 
years. They reported an increased prevalence of 
wheeze in these children up to the age of 11 and 
persistently impaired lung function until age 13 
(95). Sigurs and colleagues investigated a more 
severely affected group of children who had been 
hospitalized with RSV lower respiratory tract 
infection in the first year of life. Their findings 
correlated with those seen in the less severely 
affected children; with an increased prevalence of 
asthma/recurrent wheeze as well as atopy and 
clinical allergy which persisted throughout 
childhood (2). Indeed the data collected from 
these participants at age 18 continued to show 
differences between healthy controls and affected 
individuals both in the relative rates of allergy, 
asthma and recurrent wheeze as well as 
abnormalities in lung function. They postulated 
that persistent clinical and lung function 
abnormalities represent the consequences of 
airway remodelling stimulated by early RSV 
infection. The potential pathogenic mechanisms 
for this remain unclear although impaired T-
regulatory function, persistent activation of innate 
immunity and an early Th2 helper switch have 
been implicated (96).  
Debate remains as to the extent which early RSV 
infection is causal of later airway disease, by 
altering immune responses and subsequent airway 
maturation, or whether children with a 
predisposition to wheeze and asthma are more 
likely to develop severe RSV infection. To address 
this question, a double-blind placebo controlled 
trial was designed to investigate if prevention of 
RSV, using the monoclonal antibody palivizumab 
during RSV season, would impact on subsequent 
rates of wheeze. The results demonstrated a 
substantial reduction in episodes wheeze for up to 
one year in healthy preterm babies in the 
treatment group compared to those in the placebo 
group (97). Of note, the effect of palivizumab on 
wheeze reduction persisted even after treatment 
had been stopped and RSV season was complete, 
suggesting that wheeze reduction was not simply 
attributable to fewer acute RSV episodes. The 
authors thus argue their findings support the 
concept of RSV as a pathogenic stimulus in the 
development of recurrent wheeze. They postulate 
that epithelial damage from RSV infection alters 
local pulmonary immune responses resulting in 
airway hyper-responsiveness. However, the testing 
of a high-potency derivative of palivizumab 
(motavizumab) showed no such effect in term 
babies, despite a substantial reduction in hospital 
admissions and non-inferiority compared to 
palivizumab (98,99). The reasons for the disparity 
between these two monoclonal drugs are unclear 
and may simply be evidence against a direct causal 
relationship between RSV and subsequent wheeze.  
Another possible explanation lies in the 
differences between the study populations; with 
the palivizumab study investigating outcomes in 
preterm babies and based on parent-reported 
episodes of wheeze whereas the motavizumab 
study examined healthy term infants and relied on 
medically attended wheezing episodes (99). 
Presentation in Adults 
For the majority of adults infected with RSV the 
extent of symptoms is minimal, with non-specific 
features of a viral upper respiratory tract infection 
including coryza, sore throat, fever and malaise as 
well as lower respiratory tract symptoms such as 
cough (100). Those with underlying immune 
compromise, cardiorespiratory disease or the 
elderly can experience significantly more morbidity 
and mortality (9,10). The presentation of RSV in 
elderly patients is similar to that seen in younger 
adults, although with a greater severity and 
increased likelihood of lower respiratory tract 
involvement (100). Typically, an RSV illness begins 
with nasal congestion before progressing to cough 
in 90-97% (9,101).  Compared to influenza, 
systemic symptoms including fever, myalgia and 
gastrointestinal complaints are less common (102). 
In contrast to other respiratory tract viral 
infections, wheeze is frequently noted, even in 
those without underlying airway disease.  Audible 
crackles on chest examination and infiltrates on 
chest radiograph occur in 30-50% of elderly 
patients (9). 
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In addition to these common respiratory 
symptoms, immunocompromised patients are 
predisposed to otalgia and clinical or radiological 
evidence of sinusitis in these individuals can be 
useful in distinguishing RSV from other viral causes 
of infection including cytomegalovirus (CMV) 
(100,103). Chest radiographs in these patients are 
frequently abnormal, ranging from interstitial 
infiltrates to alveolar shadowing and pleural 
effusions. The severity of infection is closely linked 
to the degree of immune compromise with bone 
marrow transplant recipients being at greatest 
risk. Such patients have pneumonia rates of up to 
79% and mortality of 78% post-transplant 
following infection with RSV (104). 
RSV can also cause a deterioration of underlying 
cardiorespiratory disease. Estimating the 
percentage of acute exacerbations of COPD 
attributable to RSV infection is difficult as the 
appropriate viral diagnostic tests are not routinely 
employed in clinical practice, but estimates range 
up 22% (105). Whilst asthma exacerbations are 
primarily triggered by rhinovirus, RSV and 
influenza infection are important contributors to 
morbidity (106,107). In patients with lung 
transplants, infection with RSV can result in an 
acute pneumonitis presenting with increasing 
breathlessness, cough, wheeze and a fall in lung 
function (108). 
As with children, longer term complications can be 
seen in adults following recovery from acute RSV 
infection. In patients with COPD, a permanent 
decline in lung function following the clinical 
recovery from an exacerbation is well documented 
(109). Likewise, in lung transplant recipients RSV 
infection has been implicated in the development 
of chronic graft dysfunction characterised by 
obliterative bronchiolitis (110) with small airway 
remodelling and air trapping. Evidence for the 
persistence of RSV infection with the development 
of a latent state, has been reported in a variety of 
animal models and observational human studies 
(111). Although not all studies have supported this 
hypothesis (112), the potential impact of 
persistent infection not only as a reservoir for 
ongoing viral transmission, but also in 
perpetuating pulmonary immunopathology could 
be significant. 
 
LABORATORY DIAGNOSIS 
The American Academy of Pediatrics (AAP) do not 
recommend routine use of laboratory techniques 
to diagnose RSV bronchiolitis, which should 
primarily be based on clinical assessment (113). 
However, due to the many acute viral and 
bacterial respiratory infections that cause 
symptoms similar to RSV, an accurate laboratory 
diagnosis is important and will in the future permit 
the delivery of specific therapy. Broad-spectrum 
intravenous antibiotics should be avoided in 
patients with RSV bronchiolitis, since serious 
bacterial co-infections are uncommon (114). In 
addition, accurate diagnosis helps in institution of 
appropriate infection control measures and in 
facilitation of discharge planning (115). RSV 
detection can be performed using culture and non-
culture methods, the latter consisting of either 
antigen or nucleic acid detection.  
Viral Culture 
The use of cell lines to propagate virus is a long-
established technique to diagnose RSV infection. 
Traditional tube culture is efficient and 
comprehensive, allows for strain typing and 
genetic characterization as well as antiviral 
susceptibility testing (116)(117). The 3-7 day 
turnaround time however is more suitable for 
research studies or the investigation of complex 
cases and during outbreaks.  
The clinical sample can also be centrifuged on to a 
single layer of cells using the shell vial culture 
method or by the use of a cluster tray of vials, 
which can reduce processing time to 1-2 days 
making it more useful for patient management. 
Due to the labor-intensive nature and technical 
expertise required for the technique, it is largely 
restricted to reference laboratories and large 
teaching hospitals [6, 7]. The labile nature of RSV 
also means it can lose viral infectivity rapidly 
unless there is proper storage and rapid transport 
of specimens for laboratory testing. 
Antigen Detection 
This technique relies on identifying RSV antigenic 
fragments by viewing fluorescently labelled 
proteins under a microscope (direct 
immunofluorescence assay - DFA) or using a 
commercially available rapid antigen detection test 
(RADT)(119). DFA has the advantage of ensuring a 
higher degree of accuracy in identifying the 
organism and can be performed in less than an 
hour but requires expertise in reviewing specimens 
(117). It has a reported sensitivity and specificity of 
up to 94% and 96% respectively when compared 
to real-time PCR (120).  
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Rapid antigen detection tests (RADT) include 
enzyme immunosorbent assays (EIA) and 
chromatographic immunoassays (CIA) and have 
broad appeal due to their ease of use and 
applicability as a point of care test, with 
turnaround times as little as 10 minutes, allowing 
for early delivery of appropriate therapy (119). A 
Cochrane review of RCTs, which included 759 
children presenting to emergency departments 
with febrile illness and respiratory symptoms 
concluded however that whilst the use of rapid 
viral testing reduced radiological investigations it 
did not have any impact on length of their visit to 
the emergency department (121). Overall, antigen 
detection tests have a range of 80-90% sensitivity 
in comparison with culture but are prone to higher 
false positive rates outside of the peak RSV season 
and are considerably less reliable in older children 
and adults, who have reduced viral load compared 
to young children (122–124). This group may 
benefit from use of either culture or nucleic acid 
amplification testing (NAAT) to detect RSV.  
Nucleic Acid Detection  
Molecular tools such as NAAT have transformed 
the ability to identify causative organisms in ARI 
and have the distinct advantages of both speed 
and accuracy over viral culture and RADT 
respectively (4,117). Despite this only 15% of 
laboratories in the United States use the 
technique, which costs $35-125 for each sample 
tested (vs. $2-7 for DFA and $4 for culture (116)) 
as well as the equipment and specialist skills 
required (124).  
Reverse Transcriptase PCR (RT-PCR) has been 
proven to be as sensitive as culture in detecting 
RSV in hospital (125,126)  and community settings 
(5,8) in both adults and children. This technique 
has also been used to highlight minimal 
asymptomatic carriage of RSV in the community 
making it a more useful method of accurately 
diagnosing the disease in this setting (127). Further 
automation of such techniques will enable even 
more rapid, high throughput handling of clinical 
specimens.  
In the field of microbiology, molecular detection 
methods (rather than slower culture based 
methods which often fail to detect a significant 
number of organisms) have revolutionized the 
detection of bacterial pathogens and helped to 
identify distinct anatomical microbiomes. Similarly, 
the development of rapid multiplex PCR based 
technology that can be deployed as a point of care 
test is likely to institute a paradigm shift in the 
diagnosis of viral pathogens at an earlier stage of 
illness. This can be of particular benefit in those at-
risk groups (pre-term infants, elderly and those 
with multiple co-morbidities), who need early 
intervention or admission (119). A study of more 
than 430 clinical specimens validated the 
usefulness of this approach with the use of a 19-
valent multiplex PCR test, which included RSV and 
demonstrated a mean sensitivity of 93% and 
specificity of 99% (128). With the costs of 
multiplexing declining it could also be a promising 
approach for community based epidemiological 
studies (129). Nonetheless, issues remain about 
the correlation between detection of the viral 
nucleic acids and clinical symptoms (130) and 
multiple respiratory virus detection from the same 
patient may be indicative of the presence of 
chronic lung disease rather than severity of the 
infection (131).  
A comparison of the available laboratory 
techniques for RSV diagnosis in terms of speed, 
expertise required and relative cost is shown in 
figure 4.
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Anatomical Sampling 
Nasopharyngeal aspirates (NPA) have traditionally 
been the gold standard in diagnosing RSV 
infection(132) but head to head comparisons of 
nasal swab sampling versus aspirate have shown 
equivalent results for most respiratory viruses 
(133,134). Swabs are prone to lower detection 
rates, which may be due to the lower volume of 
sample being present on them.  
Flocked nasal swabs have better ability than NPAs 
to detect RSV due to their effect of dislodging 
virus-infected epithelial cells from the mucosa (4). 
They may be more suited to the outpatient setting, 
as they appear to be better tolerated than NPAs 
(135) and are also superior to nasal washes (136). 
Swabs can be considered for routine testing in the 
community but for hospitalized patients or if strain 
typing is required, an NPA is more appropriate. 
In immunocompromised patients, nasal wash has 
very poor sensitivity in detecting RSV, likely due to 
lower viral load, with these patients benefiting 
from lower airway sampling (137). The use of 
serology in diagnosing RSV in children is limited by 
the passive transfer of maternal antibodies and is  
 
 
 
 
 
 
not useful in adults due to the persistence of 
antibodies from repeat infections.  
 
ANTIVIRAL THERAPY AND OTHER POTENTIAL 
TREATMENTS 
Despite significant interest in disease-modifying 
therapies for RSV, the mainstay of treatment 
remains supportive. For the majority of affected 
children and adults illness is self-limiting and 
simple measures such as hydration and 
antipyretics are sufficient. In those in whom 
symptoms are more severe intensive supportive 
treatment in a supervised hospital environment 
may be required (96). 
Supportive 
The most recent guidelines from the American 
Academy of Pediatrics (AAP) (113) and The 
National Institute for Health and Care Excellence 
(NICE) (138) in the UK primarily focus on 
appropriate delivery of supplemental oxygen and 
hydration (table 1). Both guidelines advise delivery 
of supplemental oxygen using non-invasive and positive 
pressure ventilation strategies, as well as intravenous or 
nasogastric fluids if oral hydration is insufficient. In 
addition, NICE recommends consideration of 
Technical Expertise Required 
Sp
e
e
d
 
IF 
€€ 
[117][119] 
RADT 
€€ 
[124][127] 
[128] 
Viral Culture 
€ 
[116][117][118] Slow 
(Days) 
Medium 
(Hours) 
Fast 
(Minutes) 
NAT 
€€€ 
[4][119][126][127] 
Figure 4. Comparison of laboratory techniques to diagnose RSV. The figure represents estimates and is not 
to scale. The size of the circles represents the relative sensitivity of each test in detecting RSV. Relative 
approximate costs are represented as € and are for reagents [116]. Numbers in square brackets indicate the 
relevant references. RADT: rapid antigen detection test; IF: immunofluorescence; NAT: nucleic acid testing 
(PCR).  
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Based on guidelines published by the American Academy of Pediatrics [113], The National Institute of Health 
and Care Excellence [138] and reference [96]. IVIG: i.v. immunoglobulin.  
upper airway suctioning in children with 
respiratory distress, feeding difficulties or apnoea. 
Unlike NICE guidance, the AAP recommend 
nebulized saline as an optional treatment in 
children with an expected length of stay greater 
than 72 hours. This strategy has generated some 
controversy as the evidence base for its benefit 
has been conflicting. Despite their frequent  
 
empirical use, no recommendation is made 
regarding antipyretics (such as acetaminophen and 
ibuprofen), antitussives or decongestants by any of 
the most recent guidelines. Chest physiotherapy 
has not been recommended, although NICE adds 
the caveat that it can be employed if children have 
relevant co-morbidities (138).  
 
Supportive Inconclusive Not supportive 
Oxygen Ribavarin Nebulised bronchodilators 
Ventilation (invasive and non-
invasive) 
Nebulised hypertonic 
saline 
Nebulised adrenaline 
Nasogastric/i.v. fluids if unable to 
maintain oral intake 
Upper airway suctioning Steroids (oral/inhaled) 
Palivizumab for prevention in high-
risk babies 
Azithromycin Antibiotics without evidence of 
bacterial infection 
 IVIG Montelukast 
 
 
Antivirals and other Pharmacotherapy 
A variety of additional therapeutic agents have 
been used empirically for the treatment of 
bronchiolitis including systemic and inhaled 
corticosteroids, nebulized bronchodilators and 
nebulized adrenaline. Guidelines now recommend 
that clinicians do not use these therapies in the 
treatment of children with bronchiolitis (96). 
Antibiotic use is still permitted by the AAP 
guidelines if there is evidence of bacterial co-
infection but this recommendation is not made 
elsewhere (138,139). In adults with an RSV-
associated exacerbation of underlying lung disease 
the use of nebulized bronchodilators and oral 
corticosteroids remains commonplace. Some 
commentators argue that there is a theoretical risk 
that immunosuppression in this group of patients 
may potentiate the severity of viral infection via 
defects in humoral immunity  (140), but the 
evidence is poor.  
Ribavirin is currently the only licensed antiviral for 
the treatment of RSV in children, but the evidence 
is poor (141). Consequently, most current 
guidelines make either no recommendation or do 
not recommend its routine use, that is also limited 
by its toxicity, including to staff (64,141). In adults, 
ribavirin is used off-license and is usually reserved 
for those with severe immunocompromise such as 
hematopoietic stem cell transplants recipients 
(142) although the evidence base for its use is 
weak. In studies examining the effect of ribavirin      
 
 
(nebulized or systemic) in immunocompromised 
patients with RSV infection, there were trends 
towards improved outcomes with reduced 
progression to lower respiratory tract involvement 
and less all-cause mortality (27). However, none of 
these studies was sufficiently powered or robustly 
designed for definite conclusions to be drawn. The 
value of concomitant intravenous immunoglobulin 
administration alongside ribavirin also remains 
unproven (141). 
Immunoglobulins, both RSV specific and non-
specific, have also been used in the treatment of 
RSV related bronchiolitis in children. Like many 
other therapeutic interventions, the evidence base 
for this remains weak and a Cochrane review in 
2006 concluded that there was no statistically 
significant benefit of such treatment (143). 
Montelukast, a leukotriene inhibitor used in the 
treatment of asthma, has also been tried in the 
treatment of bronchiolitis. A 2015 Cochrane 
review considered five randomized control trials 
comparing montelukast treatment with placebo in 
children less than 2 years of age with a diagnosis of 
bronchiolitis. Two of the five studies examined the 
impact of montelukast acutely during the hospital 
admission whereas the other 3 studies focused on 
longer term use over several weeks following a 
diagnosis of bronchiolitis to prevent ongoing 
episodes of wheeze. The authors concluded that 
whilst none of the studies demonstrated a 
difference between montelukast and placebo, no 
Table 1. Current evidence for therapeutic options in managing RSV bronchiolitis 
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definite conclusions could be drawn due to 
statistical inconsistencies and weaknesses of the 
studies (144). 
Azithromycin, a macrolide antibiotic with 
immunomodulatory properties, was shown to 
have no impact on clinical outcome measures such 
as duration of hospital stay, oxygen 
supplementation or symptom scores when given 
to infants during acute RSV bronchiolitis (64). It 
was however, found to reduce levels of 
neutrophilic inflammation in the airways of mice in 
a murine bronchiolitis model (145). A proof of 
concept study was therefore conducted in human 
infants investigating the effectiveness of 
azithromycin compared to placebo at reducing 
post-bronchiolitis wheeze and chronic airway 
inflammation in previously healthy infants aged 1-
18 months (146). The results demonstrated that 
treatment with azithromycin for 14 days during 
the acute bronchiolitic illness prolonged the time 
to a third parent-reported wheezing episode and 
reduced the overall number of days with 
respiratory symptoms in the 50 weeks post 
treatment. However, the primary clinical outcome, 
of a reduction in the number of children 
experiencing 2 or more wheezing episodes was not 
met and the proportion of participants diagnosed 
with asthma during the follow up period was also 
no different. More promising were the findings of 
a 2007 double blind placebo control study from 
Turkey investigating the use of clarithromycin in 
infants (<7months) hospitalized with RSV 
bronchiolitis.  Statistically significant reductions in 
length of stay, need for supplemental oxygen and 
bronchodilation were reported in addition to 
fewer re-admissions with wheeze in the 
subsequent 6 months. However, this study had a 
small sample size and further studies would be 
needed to validate the findings (147). 
Several new therapeutic agents are currently in 
development pipeline. These fall broadly into four 
different groups: siRNA interference, 
immunoglobulins, fusion inhibitors and small 
molecules (96). Each aims to disrupt the 
production or action of proteins produced by RSV 
and thus limit is pathogenicity. Agents which have 
demonstrated efficacy include ALN-RSV01, which 
uses anti-sense mechanisms to disrupt viral 
protein synthesis and thus viral replication. Proof-
of-concept studies in healthy adults experimentally 
inoculated with RSV demonstrated reduced 
infection rates with concomitant use of intra-nasal 
ALN-RSV01 (148) and use of the compound in lung 
transplant patients with RSV infection has been 
shown to reduce the rate of  new or progressive 
bronchiolitis obliterans syndrome at 180 days post 
infection (149).  
Promising results have also been seen with the 
fusion inhibitor GS-5806 which reduced the viral 
load and severity of clinical disease in a double-
blind placebo controlled viral challenge study in 
healthy adult volunteers (150). More recently, a 
placebo-controlled trial of a second antiviral (ALS-
008176, that acts on the RSV polymerase L and 
inhibits viral replication in infected cells) enhanced 
viral clearance and reduced disease severity. 
Importantly, this compound appears to be 
effective even when administration was delayed 
until 12 hours after virus detection (151). 
 
VACCINES & PREVENTION OF RSV 
The lack of effective, disease-specific therapies for 
RSV alongside the significant global burden and 
cost of disease has stimulated huge interest and 
research in vaccine discovery. However, the 
development of RSV vaccines has been hampered 
by a number of factors. First, defects in both 
innate and adaptive neonatal immune responses 
make infantile vaccination problematic. In 
addition, the presence of maternal antibodies, 
despite offering valuable protection of the 
newborn child, may also suppress the 
development of intrinsic antibody responses (152).  
Although certain immunisation strategies are 
effective in neonates (e.g. BCG for tuberculosis), 
many vaccines require repeated boosters and/or 
are delayed until the child’s immune system is 
more mature (153). In addition to the challenges 
posed by the host response, RSV as a pathogen 
creates difficulties for vaccine development. In 
particular, natural infection does not result in 
durable immunity even in adults and re-infection 
with an identical strain of virus is commonplace 
(85). A successful vaccine therefore needs to 
induce immune responses more potently than 
natural infection whilst simultaneously preventing 
an excessive and pathological inflammatory 
response in the host.  
Unfortunately, this balance was not achieved by 
early vaccine attempts. In the 1960s a formalin-
inactivated vaccine was developed for use in 
infants and children. Although a similar approach 
was effective and safe with poliovirus 
immunisation, it resulted in insufficient 
neutralising antibody response and enhanced 
disease during subsequent natural infection. In 
one trial, nearly 80% of naturally infected 
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vaccinated children required hospitalisation and 
two died (154). As a result, progress in RSV 
vaccination development has been intensely 
cautious and slow.  
Strategies to enable the investigation of the 
immune response to both natural infection with 
RSV as well as the response to a variety of 
potential vaccines have frequently relied on the 
use of animal models. Unfortunately, no single 
model has been sufficient to replicate the situation 
in human infection (155). The use of human RSV 
challenge has considerable advantages over 
animal models, but these too remain imperfect. 
Adults are not the primary target of RSV vaccines 
designed to prevent infantile bronchiolitis, 
although there may be a role for vaccination of 
pregnant women, adult care-givers and those 
adults at risk of severe RSV disease. However, 
challenge studies are currently limited to normal 
healthy adults and infants, pregnant women, 
immunocompromised or frail adults cannot be 
subjected to experimental infection. Ultimately, a 
single vaccination strategy for all target groups is 
unlikely to be preferred (155). 
Despite these hurdles, a large number of potential 
vaccines are under development and the 
likelihood of one or more successful vaccine 
reaching the market within the next decade is high 
(6,155). These vaccines fall into four broad 
categories: live attenuated, subunit, vector-based 
and particulate. Each targets different mechanisms 
of immunogenicity and thus would potentially suit 
different groups of at risk individuals. Strategies 
for optimising the effect of vaccines include the 
use of maternal vaccination to enable passive 
transfer of immunity via immunoglobulin to levels 
sufficient to provide effective protection, in an 
otherwise poorly immunogenic infant. 
Immunisation would need to be delivered to the 
mother in the second or third trimester, for the  
transfer of passive immunisation to be optimal 
(152) which would be of less value for premature 
infants in whom trans-placental antibody transfer 
is inefficient.  Immunisation of individuals in 
contact with vulnerable groups such as health care 
or nursery workers or older siblings may be 
another viable alternative to reduce virus 
transmission rates through herd-immunity. 
Live attenuated vaccines show promise in infants, 
since they may safely induce local protective 
immunity. They may however be of limited 
immunogenicity and the possibility of pathological 
responses in (undiagnosed) immunodeficient 
states still remains a concern (153). Nevertheless, 
some success has been achieved and a variety of 
phase 1 and 2 clinical trials are currently 
underway. The leading contender in the field is 
Medi-559 (MedImmune/National Institute of 
Allergy and Infectious Diseases, Bethesda, MD, 
USA). This has been well tolerated by healthy 
children and infants, with the majority of 
participants mounting a detectable serological 
response or shedding of vaccine virus as detected 
by PCR (7). Trials of other live-attenuated vaccines 
are ongoing (clinicaltrials.gov identifier numbers: 
NCT02040831, NCT01893554 and NCT01852266). 
Advantages of live attenuated vaccines include 
their ability to be delivered intranasally, to 
replicate even in the presence of passively 
delivered maternal antibody and their ability to 
stimulate multiple components of the immune 
system (152). Despite these attributes, the 
potential for reversion to wild-type and for 
secondary transmission from vaccinated child to 
contacts, as well as the difficulty in producing 
sufficient attenuation has slowed progression 
towards clinical use (155). 
 
 
Panel 1: Outstanding Questions in the Field 
 What innate and adaptive immune mechanisms determine the susceptibility of infants to 
bronchiolitis? 
 Why do some people with RSV develop symptoms, whilst others remain asymptomatic? 
 Why is it possible for adults (and children) to be re-infected with the same strain of RSV? 
 What explains the variable findings with respect to the association between RSV and wheeze in 
later life? 
 What are the best correlates of protection to use in vaccine studies? 
 What are the ideal qualities of vaccines that target specific risk groups (i.e. pregnant women, adult 
care-givers, school age children and elderly persons)? 
 How can animal models be improved still further? 
 What public health measures are appropriate and feasible in resource-limited settings? 
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Some of these issues could be avoided with the 
use of subunit vaccines, which have no potential 
for infectivity in either vacinees or their contacts. 
Unfortunately, they often fail to sufficiently 
stimulate a response in the immature infant 
immune system (96) and their optimal use may 
prove to be in boosting the adult response.  
Subunit vaccines, which contain purified proteins, 
with or without the addition of immune 
stimulating adjuvants, have been shown to be 
effective in inducing neutralising antibodies in the 
serum of adults (156) and may offer an effective 
option for the elderly and pregnant women (96). In 
seronegative individuals there is a possible risk of 
vaccine-enhanced disease and hence these 
vaccines would be unlikely to be useful in 
previously unexposed neonates. Particle based 
vaccines, which consist of multiple proteins 
arranged on virus/bacteria-like structures, mimic 
infective agents and  may be able to induce 
durable immunity (155). Vector-based vaccines use 
other viruses or bacteria as a means of delivery of 
RSV genetic components. Viral protein production 
allows antigens to be made within the host, while 
the vector is rendered harmless (155). Much of the 
recent progress in vaccine development is due to 
improvements in our understanding of the 
structure and function of RSV, the immunogens 
that it makes and the protective and harmful 
immune responses that these raise in the host. A 
detailed appreciation of the host immune 
response to RSV, particularly the T and B-cell 
immune responses, are vital to future vaccine 
development.  
Strategies for prevention of RSV mainly focus on 
the use of passive immunisation. Palivizumab, a 
humanised monoclonal antibody of RSV, is 
licensed for use in high risk babies during RSV 
season, in order to prevent disease in the lower 
respiratory tract. Large randomised controlled 
studies in the late 1990s showed a reduction of 
55% in the rate of hospitalisation for RSV in 
preterm infants compared to placebo (157). 
Further studies have confirmed its efficacy and the 
American Academy of Paediatrics has recently 
produced advice as to which at risk infants benefit 
from treatment (158). Monthly administration of 
antibody is very costly, which largely limits its use 
and is of no value in established infection (155).  
As previously discussed, the potential benefits of 
RSV prevention with passive antibody could 
extend beyond  the effect on acute morbidity and 
mortality, with possible impacts on the occurrence 
of longer term sequelae such as recurrent wheeze 
(97). Of the newer monoclonal antibody 
candidates, motavizumab seemed the most 
promising (99), however its development has been 
halted due to non-superiority to palivizumab and 
adverse skin reactions. It is to be hoped that other 
monoclonals can be marketed for RSV prevention 
at lower cost. 
 
CONCLUSION 
A summary of some of the outstanding questions 
in the field of RSV research are outlined in panel 1 
and the key take-home messages of the current 
research on RSV are outlined in panel 2. RSV 
infection is currently ubiquitous during early 
childhood, causing a vast burden of disease 
throughout the world. The link between severe 
childhood infections and the development of 
longer-term respiratory ill health is intriguing, but 
as yet poorly mapped and understood and the 
proposed causal link between bronchiolitis, the 
later development of recurrent infantile wheeze 
and the diagnosis of childhood asthma remains to 
be established with certainty. While infections 
with many common and important respiratory 
pathogens (e.g. influenza virus, Haemophilus 
influenzae, Streptococcus pneumoniae) are 
vaccine-preventable, RSV has so far eluded 
vaccinologists. There is now a race on between 
those developing a large number of vaccines that 
aim to induce long-lasting protection. Field trials of 
both vaccines and antiviral drugs in real-life 
settings are keenly awaited, but for now the 
treatment of RSV disease remains largely 
supportive. The advent of antivirals and vaccines 
that reduce viral load and disease, coupled with 
increasingly sensitive molecular techniques to 
diagnose infection at an early stage, may 
potentially greatly reduce the global impact of RSV 
infection over the coming few years. Ultimately, 
such measures may have an impact on RSV’s 
ability to circulate in communities, changing the 
population dynamics of infection and altering the 
global grip of this virus.  
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 RSV is the leading cause of bronchiolitis in infants and excess winter deaths in the elderly.  
 
 It is estimated to cause 30 million acute respiratory infections in children and in excess of 60,000 
deaths worldwide each year. 
 
 RSV causes upper and lower respiratory tract infections in both children and adults. Infants and 
young children, frail elderly and those with chronic cardio-respiratory disease or immunocompromise 
are at greatest risk of morbidity and mortality. 
 
 RSV disease is predominantly a winter illness. Its incidence peaks in December to January in Northern 
European countries and February to March in Southern Europe. 
 
 Susceptibility to severe RSV disease is increased by exposure to tobacco smoke, air pollution, 
crowding (in day care, nursing home or hospitals) and the presence of school-age older siblings. 
 
 RSV infection in children has been linked to the development of asthma and atopy although a causal 
relationship remains unproven. 
 
 RSV has been classified into two distinct subgroups (A and B) based on antigenic variability with the 
suggestion that subtype A causes more severe disease. Genetic sequence analysis is the most 
accurate way of identifying viral subtypes for research purposes. 
 
 A key characteristic of RSV is its ability to evade immunity and thus to re-infect despite limited 
antigenic variation. 
 
 Laboratory diagnosis of RSV is not essential but can facilitate appropriate antibiotic stewardship. 
 
 Nasopharyngeal aspirate is the gold standard for collection of samples with flocked nasal swabs an 
acceptable alternative in community settings. Immunocompromised patients should have lower 
airway sampling and PCR diagnosis to increase the chances of a positive yield.   
 
 Culture remains the gold standard for diagnosing RSV but is being overtaken by fast molecular 
techniques. Rapid antigen detection kits are relatively inexpensive, easy point of care testing but 
limited by lower sensitivity and poor reliability in adults. Nucleic acid detection (PCR) now offers high 
sensitivity and increasingly quick turnaround times. 
 
 Hand decontamination with alcohol or soap is important in preventing nosocomial transmission. 
 
 Appropriate supportive treatment with fluids, oxygenation and ventilatory support remains the 
cornerstone of RSV management.  
 
 Salbutamol, adrenaline and systemic corticosteroids should not be routinely administered to infants 
with bronchiolitis. 
 
 There are several very promising anti-viral drugs and vaccines in development, but their impact in 
clinical settings is currently difficult to anticipate. Promising vaccination strategies include the use of 
maternal vaccines, inactivated or live vaccines for neonates and sub-unit vaccines for the elderly. 
Panel 2: Key take-home messages 
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